SEC Appoves S1 For Lansing's Kraig Biocraft

Lansing-based Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotech company focused on the development of high performance polymers and technical fiber based on the components in spider silk, announced Tuesday that its S1 registration statement has been declared effective.

The Company filed the S1 registration statement in October 2009.

Said CEO Kim K. Thompson: "The S1 registration lays the foundation for our financing program over the next twenty four months. When we originally filed the S1 our legal advisors told us that we could expect a delay of at least 45 days. Those 45 days ultimately turned into almost nine months. While we have been pursuing this clearance our legal advisors informed us that the company should limit its public communication to avoid the perception of any promotion. We want to thank all of our shareholders for their patience during this arduous process and we look forward to what we now believe will be a very successful year for Kraig Biocraft Laboratories."

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame.

More at www.KraigLabs.com.

Kraig has obtained the exclusive right, in their field of research, for the spider silk gene sequences which are at the core of their technology. These genetic sequences were first studied and subsequently patented by Randy Lewis of the University of Wyoming. In early 2006, the company obtained certain exclusive rights from the university to use the sequences in our field of use. Spider silk is among the strongest fibers produced in nature with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for high performance polymers.

© MMX WWJ Radio, All Rights Reserved.